Albireo AB
Records under this name other than the patents Albireo AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 50 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,183,920 | Crystal Modifications of Elobixibat Formerly held In force · High confidence | In force | High confidence | |
| US 10,519,120 | Crystal Modifications of Elobixibat Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,441,605 | Oral Cholestyramine Formulation and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,493,096 | Oral Cholestyramine Formulation and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 10,758,563 | Oral Cholestyramine Formulation and Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 12,060,338 | Benzothia(DI)azepine Compounds and Their Use as Bile Acid Modulators Formerly held In force · High confidence | In force | High confidence | |
| US 7,514,421 | Use of an Ibat Inhibitor for the Treatment of Constipation Term ended Term ended Apr 1, 2024 · High confidence | Term ended | Term ended Apr 1, 2024 | High confidence |
| US 7,192,945 | Benzothiazepine Derivatives Formerly held Term ended Ended no later than Dec 21, 2022 · Medium confidence | Term ended | Ended no later than Dec 21, 2022 | Medium confidence |
| US 7,132,416 | Benzothiazepine and Benzothiazepine Derivatives with Ileal Bile Acid Transport (IBAT) Inhibitory Activity for the Treatment Hyperlipidaemia Term ended Term ended Sep 5, 2022 · High confidence | Term ended | Term ended Sep 5, 2022 | High confidence |
| US 8,288,370 | Novel Substituted Azetidine Compounds of Formula (I) Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs, and Functional Dyspepsia Formerly held Lapsed on the fee record Ended Oct 16, 2020 · High confidence | Lapsed on the fee record | Ended Oct 16, 2020 | High confidence |